World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
25015
World Ranking
13747
National Ranking
409

Nobuyuki Miyasaka publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nobuyuki Miyasaka sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 505 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nobuyuki Miyasaka D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nobuyuki Miyasaka sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nobuyuki Miyasaka is affiliated with Tokyo Medical and Dental University in Japan. Their primary field of research is Medicine, with a significant focus on Rheumatology. They have contributed extensively to studies related to autoimmune and inflammatory disorders, with notable research interests spanning rheumatoid arthritis and systemic lupus erythematosus.

The scientist's work encompasses several main topics, including:

  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • HER2/EGFR in Cancer Research
  • Chronic Lymphocytic Leukemia Research
  • Autoimmune and Inflammatory Disorders Research
  • Multiple Myeloma Research and Treatments
  • Pneumocystis jirovecii pneumonia detection and treatment

Several papers authored or coauthored by Nobuyuki Miyasaka provide insight into their research focus. Notable recent publications include:

  • Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study, published in 2020 in Lara D. Veeken
  • Chondroprotective effects of CDK4/6 inhibition via enhanced ubiquitin-dependent degradation of JUN in synovial fibroblasts, published in 2021 in Lara D. Veeken
  • An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up, published in 2020 in Rheumatology Advances in Practice
  • Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - A systematic review and meta-analysis, published in 2020 in Modern Rheumatology
  • Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis, published in 2020 in International Journal of Rheumatic Diseases

Miyasaka frequently publishes in specific venues, reflecting their engagement with leading journals in rheumatology and related fields:

  • Lara D. Veeken
  • Rheumatology Advances in Practice
  • Modern Rheumatology
  • International Journal of Rheumatic Diseases
  • Arthritis Research & Therapy

The scientist often collaborates with several coauthors across their work, including:

  • Takahiko Sugihara
  • Tadashi Hosoya
  • Hiroyuki Baba
  • Fumio Hirano
  • Masayoshi Harigai

Subfields of study for Nobuyuki Miyasaka extend beyond rheumatology to include genetics, hematology, oncology, and epidemiology, showing a multidisciplinary approach to medical research.

Best Publications

  • Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

    Norihiro Nishimoto;Kazuyuki Yoshizaki;Nobuyuki Miyasaka;Kazuhiko Yamamoto

  • Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

    Norihiro Nishimoto;Jun Hashimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto

  • Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis

    T Hirano;T Matsuda;M Turner;N Miyasaka

  • Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides

    H Sakurai;H Kohsaka;M F Liu;H Higashiyama

  • Disruption of the Bcl6 Gene Results in an Impaired Germinal Center Formation

    Tetsuya Fukuda;Takehiko Yoshida;Seiji Okada;Masahiko Hatano

  • Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

    Norihiro Nishimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto;Shinichi Kawai

  • Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

    Norihiro Nishimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto;Shinichi Kawai

  • Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity

    Takashi Fujibayashi;Susumu Sugai;Nobuyuki Miyasaka;Yoshio Hayashi

  • Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

    Y Tanaka;T Takeuchi;T Mimori;K Saito

  • Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction.

    Nobuyuki Miyasaka;Kazuto Sato;Makoto Goto;Minoru Sasano

  • Excessive Production of IFN-γ in Patients with Systemic Lupus Erythematosus and Its Contribution to Induction of B Lymphocyte Stimulator/B Cell-Activating Factor/TNF Ligand Superfamily-13B

    Masayoshi Harigai;Manabu Kawamoto;Masako Hara;Tetsuo Kubota

  • Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway.

    Hiroshi Chin;Ayako Arai;Hiroshi Wakao;Ryuichi Kamiyama

  • Specificity of antibodies to type II collagen in rheumatoid arthritis.

    Kuniaki Terato;Kuniaki Terato;Yasunori Shimozuru;Kou Katayama;Yoshiharu Takemitsu

  • Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis.

    Ken Taniguchi;Hitoshi Kohsaka;Naoki Inoue;Yoshio Terada

  • Chemokines Regulate IL-6 and IL-8 Production by Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis

    Toshihiro Nanki;Kenji Nagasaka;Kenji Hayashida;Yuji Saita

  • Amelioration of Collagen-Induced Arthritis by Blockade of Inducible Costimulator-B7 Homologous Protein Costimulation

    Hideyuki Iwai;Yuko Kozono;Sachiko Hirose;Hisaya Akiba

  • Upregulated expression of chemokines in herniated nucleus pulposus resorption.

    Hirotaka Haro;Kenichi Shinomiya;Hiromichi Komori;Atsushi Okawa

  • Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption.

    Fumitaka Mizoguchi;Yayoi Izu;Tadayoshi Hayata;Hiroaki Hemmi

  • Pneumocystis pneumonia associated with infliximab in Japan.

    Masayoshi Harigai;Ryuji Koike;Nobuyuki Miyasaka

  • Decreased autologous mixed lymphocyte reaction in Sjögren's syndrome.

    N Miyasaka;B Sauvezie;D A Pierce;T E Daniels

Frequent Co-Authors

Tsutomu Takeuchi
Tsutomu Takeuchi Keio University
Yoshiya Tanaka
Yoshiya Tanaka University of Occupational and Environmental Health Japan
Takao Koike
Takao Koike Hokkaido University
Hisashi Yamanaka
Hisashi Yamanaka International University of Health and Welfare
Naoki Ishiguro
Naoki Ishiguro Nagoya University
Kusuki Nishioka
Kusuki Nishioka St. Marianna University School of Medicine
Katsumi Eguchi
Katsumi Eguchi Nagasaki University
Tatsuya Atsumi
Tatsuya Atsumi Hokkaido University
Noboru Mizushima
Noboru Mizushima University of Tokyo

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in the healthcare field can complement or diversify your medical education. Many professionals consider graduate programs in healthcare administration. When selecting a management track, it’s important to understand how to evaluate healthcare administration degree programs for accreditation, flexibility, and career outcomes.

Practicing nurses aiming to advance may look for reputable bridge programs. There are accredited rn to bsn online no clinicals accredited programs that eliminate the need for on-site clinicals, making it easier for working professionals to earn their BSN remotely.

For nurses interested in leadership or advanced practice roles, doctoral degrees are available through online pathways. Some of the fastest msn to dnp program options offer accelerated completion timelines, helping you reach your goals faster. Those seeking a less intensive workload can explore the easiest dnp programs, which offer greater flexibility while still leading to valuable doctoral credentials.

These related online pathways expand your career options in the health sector—whether you are just starting or looking to advance your expertise in medicine or healthcare administration.

Best Scientists Citing Nobuyuki Miyasaka

Trending Scientists

Recently Published Articles